Product Overview: MODAFINIL (Pharma-Grade
Modafinil is a wakefulness-promoting compound classified as a eugeroic agent, extensively studied for its unique neurochemical mechanisms and cognitive enhancement properties. Originally developed for sleep disorder research, this pharma-grade formulation provides researchers with precisely dosed 100mg tablets manufactured to pharmaceutical standards. Each bottle contains 30 tablets from milpharma, ensuring consistent dosing across extended laboratory protocols. The compound’s distinctive mechanism of action involves dopamine transporter inhibition, histamine signalling modulation, and orexin system activation, making it particularly valuable for neurological research applications.
Research institutions investigating cognitive enhancement pathways will find modafinil particularly useful due to its well-documented pharmacokinetic profile and extensive clinical data. The compound demonstrates high oral bioavailability and predictable metabolism patterns, crucial factors for reproducible research outcomes. Studies have examined modafinil’s effects on executive function, working memory consolidation, and attention span enhancement in various research models. Its unique neurochemical footprint distinguishes it from traditional stimulants, offering researchers opportunities to study alternative cognitive enhancement mechanisms. Scientists at Stroid UK Shop can access comprehensive research materials alongside specialized compounds including selective androgen receptor modulators and research peptides for diverse experimental protocols.
Laboratory Applications
Researchers study modafinil across multiple neurological research domains, particularly investigating its neuroprotective properties and cognitive enhancement mechanisms. The compound’s ability to modulate dopaminergic, noradrenergic, and histaminergic neurotransmission systems makes it valuable for examining complex neural pathway interactions. Sleep research laboratories utilize modafinil to investigate circadian rhythm disruption and recovery mechanisms, while cognitive research facilities examine its effects on memory formation and attention maintenance. Neuroplasticity studies have incorporated modafinil to evaluate synaptic adaptation and neural network reorganization patterns. The compound’s pharmacokinetic properties allow for precise timing in experimental protocols, with peak plasma concentrations occurring 2-4 hours post-administration and elimination half-life extending 12-15 hours. Research teams investigating age-related cognitive decline have examined modafinil’s potential neuroprotective effects against oxidative stress and neuroinflammation. Brain and memory support research protocols frequently incorporate modafinil alongside other cognitive enhancement compounds to evaluate synergistic effects and comparative mechanisms.
Product Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Modafinil |
| CAS Number | 68693-11-8 |
| Molecular Formula | C₁₅H₁₅NO₂S |
| Molecular Weight | 273.35 g/mol |
| Dosage Form | Pharmaceutical Tablets |
| Strength | 100mg per tablet |
| Quantity | 30 tablets per bottle |
| Manufacturer | milpharma |
| Storage Conditions | Room temperature, dry environment |
| Shelf Life | Verify with supplier |
Research Compliance
These modafinil tablets are manufactured exclusively for in-vitro laboratory research and analytical testing purposes. This product is not intended for human consumption, clinical application, or therapeutic use. Research institutions must maintain appropriate licensing and safety protocols when handling this compound. All studies should be conducted by qualified researchers in approved laboratory facilities following institutional guidelines and regulatory requirements.
